ProPhase Labs, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Earnings Per Share (Tables)

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Basic and Diluted Net Loss Per Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):


	For the years ended
	December 31, 2023		December 31, 2022
Net (loss) income - basic	$	(16,782)	$	18,463
Interest on unsecured convertible promissory note	—		632
Net (loss) income - diluted	$	(16,782)	$	19,095
Weighted average shares outstanding - basic	17,207		15,845
Diluted shares- Stock Options	—		1,493
Diluted shares- Stock Warrants	—		1,073
Unsecured convertible promissory note	—		240
Weighted average shares outstanding - diluted	$	17,207	$	18,651

Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):


	For the years ended
Anti-dilutive securities	December 31, 2023	December 31, 2022
Common stock purchase warrants	831	455
Stock Options	2,951	770
Anti-dilutive securities	3,782	1,225